Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients
A Phase III, Double-Blind, Randomized, Placebo-Controlled Study of Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- Phase 3
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female postoperative radical neck surgery patients with histologically proven Stage III or IV (without distant metastases) epidermoid (squamous cell) carcinoma of the head and neck limited to the following locations as defined by the American Joint Commission (AJC): lip and oral cavity, pharynx, or larynx.
- Postoperative radical patients whose specimen had a) microscopic positive tumor cell margins (< 2mm from surgical margin) or b) extranodal capsular spread (perineural-vascular embolization) or c) two or more positive nodes
- Postoperative radical neck patients must have received Radiotherapy (RT).
- Performance status of ≥ 70 on the Karnofsky Performance Score (KPS) at screening.
- Patients ≥ 18 years of age
- Patients must have provided written informed consent prior to participation in the trial.
- Patients must have demonstrated an educational level and a degree of understanding such that they could communicate effectively with the investigator.
Exclusion Criteria:
- Patients that received any prior chemotherapy including mitomycin-C or porfiromycin.
- Treatment with granulocyte, granulocyte-macrophage stimulating factor (G-CSF, GM-CSF) or Interleukin-11 within 30 days prior to start of RT.
- RT within the treatment field for any malignancy within the past five years.
- Patients who had any gross (visible or palpable) residual disease left after surgery.
Patients who met any of the following clinical laboratory criteria upon screening:
- Granulocyte (neutrophil) count of < 1,500/cubic millimeters (mm3)
- Platelets < 75,000/mm3
- Prothrombin time (PT) and partial thromboplastin time (PTT) > 1.5 times the upper limit of normal (ULN) in seconds.
- Women who were pregnant or nursing.
- Women of childbearing potential who were unwilling to utilise a medically acceptable method of contraception (oral contraceptives, intrauterine devices, diaphragm or subdermal implants eg: Norplant®).
- Other malignancies active within the past five years (other than basal or squamous cell carcinomas of the skin outside the planned radiation portals, or in situ carcinoma of the cervix).
- The presence of more than one primary tumor or presence of distant metastases.
- The presence of any other life-threatening illness, such a severe chronic lung, liver, or heart disease that would be expected to be fatal within five years, regardless of the patient's cancer status.
- Patients who participated in a clinical trial with another investigational drug or treatment 30 days prior to screening.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Porfiromycin + Radiotherapy
|
|
|
Comparateur placebo: Placebo + Radiotherapy
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Time to Disease Progression
Délai: week 4 and 8 post treatment, every 8 weeks until end of study
|
week 4 and 8 post treatment, every 8 weeks until end of study
|
|
Maximum toxicity grades of Adverse Events (AE)
Délai: until 42 days after end of treatment
|
until 42 days after end of treatment
|
|
Time to non-accidental death
Délai: week 4 and 8 post treatment, every 8 weeks until end of study
|
week 4 and 8 post treatment, every 8 weeks until end of study
|
|
Serum porfiromycin concentration-time profile
Délai: up to week 7
|
up to week 7
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Death for any reason
Délai: 4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
|
Loss of local or regional control, distant metastasis or death for any reason
Délai: 4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
|
Loss of local or regional control or distant metastasis
Délai: 4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
|
Loss of local or regional control
Délai: 4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
|
Occurrence of Adverse Events
Délai: up to week 16
|
up to week 16
|
|
Significant changes in laboratory tests
Délai: up to week 7
|
up to week 7
|
|
Changes from baseline in Patients health related Quality of life-Questionnaires
Délai: week 1, 5, 7, 4 weeks post treatment, every 12 weeks until end of study
|
week 1, 5, 7, 4 weeks post treatment, every 12 weeks until end of study
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 1164.4
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .